These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 30030604)
1. Changes and innovations of the 2017 ESC guidelines on dual antiplatelet therapy in coronary artery disease-a review. Alber HF; Huber K Wien Klin Wochenschr; 2018 Dec; 130(23-24):694-697. PubMed ID: 30030604 [TBL] [Abstract][Full Text] [Related]
2. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Valgimigli M; Bueno H; Byrne RA; Collet JP; Costa F; Jeppsson A; Jüni P; Kastrati A; Kolh P; Mauri L; Montalescot G; Neumann FJ; Petricevic M; Roffi M; Steg PG; Windecker S; Zamorano JL; Levine GN; Eur J Cardiothorac Surg; 2018 Jan; 53(1):34-78. PubMed ID: 29045581 [No Abstract] [Full Text] [Related]
3. Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease. Thompson PL; Verheugt FW Clin Ther; 2014 Sep; 36(9):1176-81. PubMed ID: 25234549 [TBL] [Abstract][Full Text] [Related]
4. Effects of endothelial dysfunction on residual platelet aggregability after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. Fujisue K; Sugiyama S; Ono T; Matsuzawa Y; Akiyama E; Sugamura K; Matsubara J; Kurokawa H; Kaikita K; Iwashita S; Sumida H; Hokimoto S; Oniki K; Nakagawa K; Matsui K; Ogawa H Circ Cardiovasc Interv; 2013 Aug; 6(4):452-9. PubMed ID: 23922147 [TBL] [Abstract][Full Text] [Related]
5. [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.]. Valgimigli M; Bueno H; Byrne RA; Collet JP; Costa F; Jeppsson A; Jüni P; Kastrati A; Kolh P; Mauri L; Montalescot G; Neumann FJ; Peticevic M; Roffi M; Steg PG; Windecker S; Zamorano JL Kardiol Pol; 2017; 75(12):1217-1299. PubMed ID: 29251754 [No Abstract] [Full Text] [Related]
6. Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease. Collet JP; Roffi M; Byrne RA; Costa F; Valgimigli M; ; ; Eur Heart J; 2018 Jan; 39(3):e1-e33. PubMed ID: 29088328 [No Abstract] [Full Text] [Related]
7. Antithrombotic regimens in patients with atrial fibrillation and coronary artery disease after percutaneous coronary intervention: A focused review. Chang KW; Arbit B; Hsu JC Int J Cardiol; 2017 Sep; 243():263-269. PubMed ID: 28595745 [TBL] [Abstract][Full Text] [Related]
8. [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: What is new?]. Öngen Z Turk Kardiyol Dern Ars; 2018 Jan; 46(1):1-6. PubMed ID: 29339684 [No Abstract] [Full Text] [Related]
9. [Adherence to antiplatelet therapy in patients with coronary artery disease]. Legrand D; Legrand V Rev Med Liege; 2010; 65(5-6):304-10. PubMed ID: 20684411 [TBL] [Abstract][Full Text] [Related]
11. [Oral anticoagulants in elderly patients with coronary artery disease and atrial fibrillation]. Gallet R; Teiger E Ann Cardiol Angeiol (Paris); 2018 Dec; 67(6):404-410. PubMed ID: 30342831 [TBL] [Abstract][Full Text] [Related]
12. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. ; Bittl JA; Baber U; Bradley SM; Wijeysundera DN Circulation; 2016 Sep; 134(10):e156-78. PubMed ID: 27026019 [TBL] [Abstract][Full Text] [Related]
13. Antiplatelet for Coronary Artery Disease in Specific Condition "No Size Fits All". Setiadi BM; Hartono B; Prakoso AB; Lubis AC; Munandar RM; Munawar M Curr Pharm Des; 2018; 24(4):478-495. PubMed ID: 29424303 [TBL] [Abstract][Full Text] [Related]
14. Antiplatelet effect of aspirin in patients with coronary artery disease. Grove EL Dan Med J; 2012 Sep; 59(9):B4506. PubMed ID: 22951204 [TBL] [Abstract][Full Text] [Related]
16. Updates in antiplatelet agents used in cardiovascular diseases. Cheng JW J Cardiovasc Pharmacol Ther; 2013 Nov; 18(6):514-24. PubMed ID: 24213473 [TBL] [Abstract][Full Text] [Related]
17. Role of antiplatelet therapy across the spectrum of patients with coronary artery disease. Bhatt DL Am J Cardiol; 2009 Feb; 103(3 Suppl):11A-19A. PubMed ID: 19166708 [TBL] [Abstract][Full Text] [Related]
18. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. Lopes RD; Rao M; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Go AS; Hylek EM; Kowey P; Piccini JP; Singer DE; Chang P; Peterson ED; Mahaffey KW Am J Med; 2016 Jun; 129(6):592-599.e1. PubMed ID: 26797080 [TBL] [Abstract][Full Text] [Related]
20. A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial. Wenaweser P; Eshtehardi P; Abrecht L; Zwahlen M; Schmidlin K; Windecker S; Meier B; Haeberli A; Hess OM Thromb Haemost; 2010 Sep; 104(3):554-62. PubMed ID: 20664903 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]